Borisy Alexis 4

What Happened Alexis Borisy, a director of Revolution Medicines (RVMD), was granted equity awards on June 18, 2026: 1,191 restricted stock units (RSUs) and a derivative award covering 3,127 shares (an option‑style grant). Both awards were reported at $0.00 purchase price (compensation grants), so no cash changed hands.

Key Details

• Transaction date: 2026-06-18; Price: $0.00 for both items.
• Awards reported: 1,191 RSUs (F1) and a 3,127‑share derivative/option grant (A, derivative).
• Shares owned after the transaction: not specified in the Form 4 provided.
• Footnotes: F1 confirms the 1,191 items are RSUs. F2 states the option vests in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the next Annual Meeting, subject to continued service.
• Filing timeliness: Form 4 was filed on 2026-06-23 for a 2026-06-18 transaction (filed after the SEC’s usual two-business-day deadline), indicating a late filing.

Context These were compensation awards (RSUs and an option-like grant), not open‑market purchases or sales; such awards are commonly part of director compensation and do not by themselves indicate buying or selling sentiment. The derivative grant is subject to vesting conditions per F2 and does not represent immediately tradable shares until vested (and any applicable exercise is completed).